Alemtuzumab Improves Cognitive Processing Speed in Active Multiple Sclerosis-A Longitudinal Observational Study.

Front Neurol · 2017 · PMC5775967 · PMID 29387035

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Additionally, the proportion of patients impaired in ≥3 tests was reduced from 24% at baseline to 14% at follow-up, even though this result did not reach statistical significance, possibly due to small sample size and low statistical power.

also in 111,027 other papers

showed a trendno p-value reported

During the treatment period, the median percentile rank of all cognitive measures showed a trend toward improvement.

also in 53,322 other papers

a statistical trendno p-value reported

Overall Cognitive Change The median percentile rank of 35.24 ( SD = 22.42) at baseline improved to 42.96 (SD = 19.78) at follow-up ( p = 0.086), indicating a statistical trend toward overall cognitive improvement.

also in 2,798 other papers

failed to reach statistical significanceno p-value reported

Using McNemar’s test for paired samples, these changes failed to reach statistical significance (all p s > 0.05).

also in 6,035 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.